2
ALL1
Accord healthcare1
Dr. Reddy's Laboratories
Year
2
ALL1
20221
2021
DEALS // DEV.
2
ALL2
Developments
Country
2
ALL1
INDIA1
UNITED KINGDOM
2
ALL2
Inapplicable
Therapeutic Area
2
ALL2
Oncology
Study Phase
2
ALL2
Approved FDF
Deal Type
2
ALL2
Inapplicable
Product Type
2
ALL2
Cytotoxic Drug
Dosage Form
2
ALL1
Intravenous Infusion1
Lyophilized Powder for Injection
Lead Product
2
ALL2
Carmustine
Target
2
ALL2
DNA synthesis
Lead Product(s) : Carmustine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dr. Reddy's Laboratories Announces the Launch of Carmustine for Injection, USP in the U.S. Market
Details : Carmustine for Injection, USP, a therapeutic equivalent generic version of BiCNU® (carmustine for injection) used to treat brain tumors, Hodgkin's disease, multiple myeloma, and non-Hodgkin's lymphoma.
Product Name : Carmustine-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
October 15, 2021
Lead Product(s) : Carmustine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Carmustine
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Accord Healthcare Launches Generic Drug for Treating Brain Tumors & Blood Cancers
Details : Carmustine is an anti-cancer ("antineoplastic") chemotherapy drug classified as an alkylating agent. It works by helping to halt the growth of cancer cells (cancer cell division).
Product Name : Carmustine-Generic
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 23, 2022
Lead Product(s) : Carmustine
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
